A5045040522- Nanoplatforms for cancer theranostics
- Nanoparticle-Based Drug Delivery
- Cancer Research and Treatments
- interferon and immune responses
- Immune cells in cancer
- Cancer, Hypoxia, and Metabolism
- PARP inhibition in cancer therapy
- Extracellular vesicles in disease
- BRCA gene mutations in cancer
- Advanced biosensing and bioanalysis techniques
- DNA Repair Mechanisms
First Affiliated Hospital of Jinan University
2022-2023
Jinan University
2023
Abstract Combined treatment of immunotherapy and radiotherapy shows promising therapeutic effects for the regression a variety cancers. However, even multi‐modality therapies often fail to antagonize large tumors due extremely immunosuppressive tumor microenvironment (TME). Here, radioimmunotherapeutic paradigm based on stimulator interferon genes (STING)‐dependent signaling is applied preclude progression by utilizing metal‐cyclic dinucleotide (CDN) nanoplatform, which integrates STING...
Large Tumor Therapy In article number 2203227, Yanyu Huang, Liangping Luo, Zeyu Xiao, and co-workers report a localized radioimmunotherapeutic regimen by using X-ray irradiation metal-cyclic dinucleotide-containing nanomodulator for the treatment of large tumors. This combined paradigm amplifies STING signaling pathway elevating production 2′,3′-cGAMP activating both systematic anti-tumor immunity.
Background: Olaparib, a poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor has demonstrated promising efficacy in patients with triple-negative breast cancer (TNBC) carrying gene (BRCA) mutations. However, its impact on BRCA wild-type (BRCAwt) TNBC is limited. Hence, it crucial to sensitize BRCAwt cells olaparib for effective clinical practice. Novobiocin, DNA theta (POLθ) inhibitor, exhibits sensitivity towards BRCA-mutated that have acquired resistance PARP inhibitors....